- Home
- REVB vs ATXG Comparison
REVB vs ATXG Comparison
Compare REVB & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ATXG
- Stock Information
- Founded
- REVB 2020
- ATXG 2014
- Country
- REVB United States
- ATXG China
- Employees
- REVB N/A
- ATXG N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ATXG Professional Services
- Sector
- REVB Health Care
- ATXG Consumer Discretionary
- Exchange
- REVB Nasdaq
- ATXG Nasdaq
- Market Cap
- REVB 4.4M
- ATXG 3.8M
- IPO Year
- REVB N/A
- ATXG N/A
- Fundamental
- Price
- REVB $1.55
- ATXG $0.63
- Analyst Decision
- REVB
- ATXG
- Analyst Count
- REVB 0
- ATXG 0
- Target Price
- REVB N/A
- ATXG N/A
- AVG Volume (30 Days)
- REVB 890.8K
- ATXG 302.5K
- Earning Date
- REVB 11-07-2025
- ATXG 11-13-2025
- Dividend Yield
- REVB N/A
- ATXG N/A
- EPS Growth
- REVB N/A
- ATXG N/A
- EPS
- REVB N/A
- ATXG N/A
- Revenue
- REVB N/A
- ATXG $4,310,835.00
- Revenue This Year
- REVB N/A
- ATXG N/A
- Revenue Next Year
- REVB N/A
- ATXG N/A
- P/E Ratio
- REVB N/A
- ATXG N/A
- Revenue Growth
- REVB N/A
- ATXG N/A
- 52 Week Low
- REVB $1.50
- ATXG $0.36
- 52 Week High
- REVB $60.48
- ATXG $1.86
- Technical
- Relative Strength Index (RSI)
- REVB 25.99
- ATXG 58.41
- Support Level
- REVB $1.50
- ATXG $0.60
- Resistance Level
- REVB $2.90
- ATXG $0.72
- Average True Range (ATR)
- REVB 0.20
- ATXG 0.07
- MACD
- REVB -0.13
- ATXG 0.01
- Stochastic Oscillator
- REVB 3.57
- ATXG 58.78
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.